Britannia biotechnologia comitatu MiNA Therapeutica ‘innovative RNA therapy may enhance liver cancer patients’ response to standard treatment. The therapy uses a double-stranded RNA that can activate a target gene called CEBPA. Packaging double-stranded RNA in lipid nanoparticles helps to penetrate into liver cells that are often difficult to reach and can control gene expression in the nucleus. It is understood that the low level expression of certain genes is related to liver cancer and other liver diseases. In laboratory studies, increasing the expression of CEBPA to restore its protein levels to normal can help reduce the growth of cancer cells.
Inter aegros accepto biotechnologico parva RNA (saRNA), duo ex illis responsionibus acceptis sorafenib integram ostenderunt, alter vero responsionem partialem post curationem cum lenvatinib ostendit. Haec est prima probatio sarnae therapiae in hominibus. Cum investigatio adhuc in primordiis suis, biotechnicorum societates nunc sperant se plura argumenta colligere.
Societas etiam sperat se idem medicamento experiri in aegrotis cum cirrhosis in futurum deducendis, et etiam cum Boehringer Ingelheim cooperatur ad alia incepta iecoris morbis perficienda. Post longum tempus evolutionis, curationes RNA magis ac magis forum ingressi sunt. MiNA dissimile therapiae quae gene expressionem excitant, maxime utuntur RNA impedimenti (RNAi) technologiae ut gene expressionem minuendi. Nuper Commissio Europaea Onpattro probata, primum RNAi medicamentum ab Alnylam elaboratum ad polyneuropathiam tractandam.
